Morgan Stanley
GANX icon

Morgan Stanley’s Gain Therapeutics GANX Stock Holding History

Morgan Stanley’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$271K Sell
139,652
-7,939
-5% -$17.3K ﹤0.01% 5738
2025
Q4 		$475K Sell
147,591
-8,084
-5% -$21.6K ﹤0.01% 5545
2025
Q3 		$276K Buy
155,675
+79,163
+103% +$134K ﹤0.01% 5755
2025
Q2 		$138K Sell
76,512
-23,283
-23% -$43K ﹤0.01% 6010
2025
Q1 		$191K Buy
99,795
+11,283
+13% +$25K ﹤0.01% 5747
2024
Q4 		$191K Buy
88,512
+83,712
+1,744% +$168K ﹤0.01% 5801
2024
Q3 		$8.54K Buy
4,800
+1,500
+45% +$1.89K ﹤0.01% 6767
2024
Q2 		$4.22K Buy
3,300
+500
+18% +$1.3K ﹤0.01% 6891
2024
Q1 		$10.6K Sell
2,800
-2,800
-50% -$11.6K ﹤0.01% 6681
2023
Q4 		$18.3K Buy
5,600
+4,300
+331% +$12K ﹤0.01% 6695
2023
Q3 		$4.26K Buy
1,300
+500
+63% +$1.9K ﹤0.01% 6946
2023
Q2 		$3.58K Hold
800
– – ﹤0.01% 7055
2023
Q1 		$3.86K Hold
800
– – ﹤0.01% 7116
2022
Q4 		$2.5K Sell
800
-252
-24% -$788 ﹤0.01% 7312
2022
Q3 		$4K Buy
1,052
+252
+32% +$947 ﹤0.01% 7299
2022
Q2 		$3K Sell
800
-3
-0.4% -$10 ﹤0.01% 7512
2022
Q1 		$3K Buy
803
+3
+0.4% +$13 ﹤0.01% 7683
2021
Q4 		$4K Hold
800
– – ﹤0.01% 7683
2021
Q3 		$6K Hold
800
– – ﹤0.01% 7446
2021
Q2 		$8K Hold
800
– – ﹤0.01% 7294
2021
Q1 		$12K Buy
+800
New +$10.5K ﹤0.01% 6885

Other funds holding GANX

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
PCM
Potomac Capital Management New York $115M AUM
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Morgan Stanley's GANX Position: Q1 2026 in Review

Morgan Stanley reduced its Gain Therapeutics (GANX) stake by 5.4% in Q1 2026, selling an estimated $17.3K and leaving 139,652 shares worth $271K. The position accounts for ﹤0.01% of the portfolio, ranked #5738.

Morgan Stanley first reported a position in GANX in Q1 2021 and has held it in 21 quarters since. The position peaked at $475K in Q4 2025. 42 funds tracked by Wall St. Rank hold GANX as of Q1 2026.

  • Morgan Stanley held 139,652 shares of Gain Therapeutics worth $271K as of Q1 2026.
  • Morgan Stanley sold 7,939 Gain Therapeutics shares in Q1 2026, an estimated $17.3K.
  • Gain Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #5738 holding.
  • Morgan Stanley first reported a position in Gain Therapeutics in Q1 2021 and has held it in 21 quarters since.
  • Morgan Stanley's Gain Therapeutics position peaked at $475K in Q4 2025.
  • 42 funds tracked by Wall St. Rank held Gain Therapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.